Clinical

Clinical ink Expands Patient Engagement Solutions with Behavioral Diagnostic Tool SPUR™

Retrieved on: 
Monday, November 13, 2023

Winston Salem, NC, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, is expanding its patient engagement suite with the inclusion of the SPUR behavioral diagnostic tool created by Observia .

Key Points: 
  • Winston Salem, NC, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, is expanding its patient engagement suite with the inclusion of the SPUR behavioral diagnostic tool created by Observia .
  • SPUR TM is a behavioral diagnostic tool that is used to determine adherence to protocol and drugs, standardize lifestyle, and modify behavior by personalized intervention.
  • The collaboration with Observia allows Clinical ink to capture a holistic view of patient behavior together with clinical outcomes and digital biomarkers.
  • We strongly share Clinical ink’s vision that improving patient experience equals improving clinical trial performance,” says Kevin Dolgin , Head of R&D at Observia.

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Retrieved on: 
Monday, November 13, 2023

Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.

Key Points: 
  • Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.
  • Total Revenues for the quarter ended September 30, 2023, were $0 compared to $0 for the quarter ended September 30, 2022.
  • Total Expenses for the quarter ended September 30, 2023 were $5.9 million compared to $4.6 million for the quarter ended September 30, 2022.
  • The loss from operations for the quarter ended September 30, 2023, was $5.9 million compared to a loss of $4.6 million for the quarter ended September 30, 2022.

Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer

Retrieved on: 
Tuesday, November 14, 2023

Humanetics Corporation, a leading innovator in medical countermeasures, is thrilled to announce the appointment of retired Rear Admiral Dr. Colin Chinn as its new Chief Medical Officer.

Key Points: 
  • Humanetics Corporation, a leading innovator in medical countermeasures, is thrilled to announce the appointment of retired Rear Admiral Dr. Colin Chinn as its new Chief Medical Officer.
  • Dr. Chinn, a distinguished medical professional and military leader, brings a wealth of knowledge and expertise to Humanetics Corporation.
  • In his new position as Chief Medical Officer at Humanetics Corporation, Dr. Chinn will guide the company's medical research and development efforts.
  • Dr. Chinn expressed his enthusiasm for his new role: “I am honored to join the exceptional team at Humanetics Corporation.

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, November 14, 2023

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.
  • Financial Highlights for Third Quarter ended September 30, 2023:
    Cash Position: Cash and cash equivalents as of September 30, 2023, were $3.2 million.
  • R&D Expenses: Research and development expenses were $1.6 million for the quarter ended September 30, 2023, compared to $0.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $1.4 million for the quarter ended September 30, 2023, compared to net loss of $2.1 million for the quarter ended September 30, 2022.

ORIEN to Present Abstracts at 65th Annual ASH Meeting Utilizing Aster Insights' Avatar Platform

Retrieved on: 
Friday, December 8, 2023

 TAMPA, Fla., Dec. 8, 2023 /PRNewswire/ -- Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced upcoming research presentations at the American Society of Hematology's (ASH) 65th Annual Meeting, December 9-12 in San Diego, CA.

Key Points: 
  • TAMPA, Fla., Dec. 8, 2023 /PRNewswire/ -- Aster Insights , the leading provider of scientific and clinical intelligence for oncology discovery, today announced upcoming research presentations at the American Society of Hematology's (ASH) 65th Annual Meeting , December 9-12 in San Diego, CA.
  • Three abstracts will be shared at this year's ASH meeting by Moffitt Cancer Center, which co-founded the Oncology Research Information Exchange Network® (ORIEN) in 2006.
  • The investigations all utilize patient data from Aster Avatar, the best-in-class, deepest multimodal dataset for discovery research in oncology.
  • "ASH is a unique opportunity to demonstrate the impactful discoveries resulting from ORIEN and Aster Insights' discovery solutions," said Anand Shah, MD, Aster Insights CEO.

PrecisePK Pioneers Model-Informed Precision Dosing and Pharmacokinetics Advancements in Argentina with Maza University

Retrieved on: 
Wednesday, December 6, 2023

Through a strategic collaboration with the reputable Faculty of Pharmacy and Biochemistry, Maza University became the inaugural institution in Argentina to acquire pivotal pharmacokinetics software.

Key Points: 
  • Through a strategic collaboration with the reputable Faculty of Pharmacy and Biochemistry, Maza University became the inaugural institution in Argentina to acquire pivotal pharmacokinetics software.
  • Maza University leverages PrecisePK for Bayesian personalized drug dosing in Argentina, advancing clinical education.
  • "The acquisition of this software is of great relevance for the academic and scientific community since it makes Maza University the first university in Argentina to acquire a Bayesian Model-Informed Precision Dosing software for the training of its students in pharmacokinetics.
  • This strategic alignment between PrecisePK and Maza University symbolizes an unprecedented fusion of academic prowess and real-world application.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Retrieved on: 
Friday, December 1, 2023

"Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.

Key Points: 
  • "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.
  • In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program.
  • Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer.
  • Exact Sciences will also host a discussion about the Oncotype DX Breast Recurrence Score test and the RSClin® Tool.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Retrieved on: 
Thursday, November 30, 2023

"Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.

Key Points: 
  • "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.
  • In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program.
  • Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer.
  • Exact Sciences will also host a discussion about the Oncotype DX Breast Recurrence Score test and the RSClin® Tool.

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on: 
Monday, November 13, 2023

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points: 
  • Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
  • Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
  • Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
  • We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on: 
Monday, November 13, 2023

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points: 
  • Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
  • Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
  • Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
  • We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."